In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.

Mitsuhiro NishiharaHitomi YamasakiRichard CzerniakHelen Jenkins

Published in: European journal of drug metabolism and pharmacokinetics (2019)

The body of evidence shows that the pharmacodynamic DDI reported between vonoprazan and clopidogrel is unlikely to be caused by the inhibition of CYP2B6, CYP2C19, or CYP3A4/5 by vonoprazan.

Keyphrases

helicobacter pylori
endoscopic submucosal dissection
acute coronary syndrome
gastroesophageal reflux disease
percutaneous coronary intervention
antiplatelet therapy
adverse drug
drug induced
emergency department
coronary artery disease
human health
atrial fibrillation